ERBB2 and cancer: The drug response profiles observed in all three FMOC02 PDCs were remarkably similar and showed continued dependency of cancer cells on the ERBB2/EGFR and RAS/ERK signalling (Fig. 5g and Supplementary Figs. 6 and 9B–D).